Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.57 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.56 |
| ▸ | NPY4R | P50391 | 4/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.51 |
| ▸ | NPY1R | P25929 | 3/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20714185 | 1.00 | KISS1R (0.57) | KISS1RPSMB5NPY4RNPY5RNPY1R | |
| SCHEMBL20714226 | 0.96 | KISS1R (0.54) | KISS1RPSMB5NPY4RNPY5RNPY1R | |
| SCHEMBL23331147 | 0.96 | KISS1R (0.54) | KISS1RPSMB5NPY4RNPY5RNPY1R | |
| SCHEMBL20714303 | 0.96 | KISS1R (0.54) | KISS1RPSMB5NPY4RNPY5RNPY1R | |
| SCHEMBL23331359 | 0.96 | KISS1R (0.59) | KISS1RPSMB5NPY4RNPY5RNPY1R | |
| SCHEMBL20714183 | 0.95 | KISS1R (0.55) | KISS1RPSMB5CTSD | |
| SCHEMBL23330990 | 0.95 | KISS1R (0.62) | KISS1RPSMB5NPY4RNPY5RNPY1R | |
| SCHEMBL20714299 | 0.95 | KISS1R (0.62) | KISS1RPSMB5NPY4RNPY5RNPY1R | |
| SCHEMBL20714498 | 0.94 | KISS1R (0.56) | KISS1RPSMB5NPY4RNPY5RNPY1R | |
| SCHEMBL20714227 | 0.92 | KISS1R (0.56) | KISS1RPSMB5NPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364275-B2 | Linear lipopeptide paenipeptins and methods of using the same | BIOVENTURES, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210128669-A1 | LINEAR LIPOPEPTIDE PAENIPEPTINS AND METHODS OF USING THE SAME | BIOVENTURES, LLC (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2019028463-A1 | LINEAR LIPOPEPTIDE PAENIPEPTINS AND METHODS OF USING THE SAME | BIOVENTURES, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364275-B2 | Linear lipopeptide paenipeptins and methods of using the same | NGLY1, VIP, CLPTM1 | KISS1R 1143/4885PSMB5 2450/4885NPY4R 1204/4885 |
| US-20210128669-A1 | LINEAR LIPOPEPTIDE PAENIPEPTINS AND METHODS OF USING THE SAME | NGLY1, VIP, CLPTM1 | KISS1R 1143/4885PSMB5 2450/4885NPY4R 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.